financetom
Business
financetom
/
Business
/
ING Comments on Euro, Sterling, Poland's Zloty
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ING Comments on Euro, Sterling, Poland's Zloty
Dec 5, 2024 3:32 AM

06:06 AM EST, 12/05/2024 (MT Newswires) -- While some may see the falling of the French government as a positive in that fiscal restraint is delayed, ING said weak business investment means France will only grow 0.6% next year.

Add in Germany contracting at 0.2% in 2025 and eurozone gross domestic product for the year comes in at just 0.7% -- with the meagre growth thanks to southern Europe.

ING sees the European Central Bank cutting rates to 1.75% next year. This should keep short-dated EUR:USD rate spreads near 200bps in favor of the US dollar all year and bring EUR/USD close to parity.

Elsewhere, GBP:USD briefly sold off and then recovered after Bank of England Governor Andrew Bailey seemed to confirm that the BoE was looking at four rate cuts over the next year, with the market only pricing three, stated ING. However, those remarks did look a bit 'technical' -- in that they merely confirmed what the BoE had been using in its models for its forecasts.

The bank will be watching closely a speech by Megan Greene, a BoE hawk, later on Thursday.

As expected, Poland's central bank (NBP) left rates unchanged at 5.75% on Wednesday and the accompanying statement didn't bring much fresh news. In detail, however, it probably shows a slightly less dovish tone than in November, wrote the bank in a note.

Given market pricing, Thursday's NBP press conference may be neutral or slightly hawkish in ING's view compared with market expectations. After Wednesday's statement, rates sold off by roughly 5bps-7bps, supporting a stronger zloty (PLN).

EUR/PLN quickly reached Wednesday's 4.280 level and the bank believes the press conference may add further support to PLN, on the other hand, current valuations seem stretched at current levels.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: US Lawmakers Push for Enforcement of Antitrust Law Against Retailers on High Food Prices
Market Chatter: US Lawmakers Push for Enforcement of Antitrust Law Against Retailers on High Food Prices
Mar 28, 2024
05:03 PM EDT, 03/28/2024 (MT Newswires) -- A group of US lawmakers is pushing the US Federal Trade Commission to enforce a price discrimination law, the Robinson-Patman Act, on findings that large retailers such as Amazon.com ( AMZN ) and Walmart ( WMT ) kept grocery prices high while boosting profit during the COVID-19 pandemic, Bloomberg reported Thursday. The lawmakers,...
Oxford Industries Fiscal Q4 Adjusted Earnings Fall, Sales Rise; Issues Guidance
Oxford Industries Fiscal Q4 Adjusted Earnings Fall, Sales Rise; Issues Guidance
Mar 28, 2024
05:02 PM EDT, 03/28/2024 (MT Newswires) -- Oxford Industries ( OXM ) reported late Thursday fiscal Q4 adjusted earnings of $1.90 per share, down from $2.28 a year earlier. Analysts polled by Capital IQ expected $1.95. Sales for the quarter ended Feb. 3 were $404.4 million, up from $382.5 million a year earlier. Analysts polled by Capital IQ expected $408.3...
Ryman Hospitality Closes Private Placement of $1 Billion Notes
Ryman Hospitality Closes Private Placement of $1 Billion Notes
Mar 28, 2024
05:02 PM EDT, 03/28/2024 (MT Newswires) -- Ryman Hospitality Properties ( RHP ) closed the $1 billion private placement of 6.50% senior unsecured notes due 2032, the real estate investment trust said Thursday. The company expects $983 million in net proceeds, which is plans to use to repay loans. ...
Applied Therapeutics Gets NDA Review Period Extension for Galactosemia Treatment -- Shares Fall After Hours
Applied Therapeutics Gets NDA Review Period Extension for Galactosemia Treatment -- Shares Fall After Hours
Mar 28, 2024
05:08 PM EDT, 03/28/2024 (MT Newswires) -- Applied Therapeutics ( APLT ) said late Thursday the US Food and Drug Administration has extended the review period by three months for its new drug application, or NDA, for govorestat to treat classic galactosemia, a rare metabolic disease. The regulator has set a new prescription drug user fee act, or PDUFA, target...
Copyright 2023-2026 - www.financetom.com All Rights Reserved